SG52240A1 - The use of cetrorelix and other nona-and decapeptides in the preparation of a medicament for combating aids and for growth stimulation - Google Patents

The use of cetrorelix and other nona-and decapeptides in the preparation of a medicament for combating aids and for growth stimulation

Info

Publication number
SG52240A1
SG52240A1 SG1996001140A SG1996001140A SG52240A1 SG 52240 A1 SG52240 A1 SG 52240A1 SG 1996001140 A SG1996001140 A SG 1996001140A SG 1996001140 A SG1996001140 A SG 1996001140A SG 52240 A1 SG52240 A1 SG 52240A1
Authority
SG
Singapore
Prior art keywords
preparation
decapeptides
nona
cetrorelix
medicament
Prior art date
Application number
SG1996001140A
Other languages
English (en)
Inventor
Bernhard Kutscher
Michael Bernd
Jurgen Prof Dr Engel
Ulf Niemeyer
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of SG52240A1 publication Critical patent/SG52240A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG1996001140A 1993-06-18 1994-04-02 The use of cetrorelix and other nona-and decapeptides in the preparation of a medicament for combating aids and for growth stimulation SG52240A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4320201A DE4320201A1 (de) 1993-06-18 1993-06-18 Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation

Publications (1)

Publication Number Publication Date
SG52240A1 true SG52240A1 (en) 1998-09-28

Family

ID=6490614

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996001140A SG52240A1 (en) 1993-06-18 1994-04-02 The use of cetrorelix and other nona-and decapeptides in the preparation of a medicament for combating aids and for growth stimulation

Country Status (24)

Country Link
US (1) US5985834A (zh)
EP (1) EP0703786B1 (zh)
JP (1) JPH08511784A (zh)
KR (1) KR100352541B1 (zh)
CN (1) CN1136915C (zh)
AT (1) ATE213164T1 (zh)
AU (1) AU688315B2 (zh)
BR (1) BR9406893A (zh)
CZ (1) CZ285997B6 (zh)
DE (2) DE4320201A1 (zh)
DK (1) DK0703786T3 (zh)
ES (1) ES2172533T3 (zh)
FI (1) FI113008B (zh)
HU (1) HUT73673A (zh)
IL (1) IL110045A (zh)
NO (1) NO320945B1 (zh)
PL (1) PL175580B1 (zh)
PT (1) PT703786E (zh)
RU (1) RU2154492C2 (zh)
SG (1) SG52240A1 (zh)
TW (1) TW370532B (zh)
UA (1) UA41938C2 (zh)
WO (1) WO1995000168A1 (zh)
ZA (1) ZA944347B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
AU2001260110B2 (en) * 1999-03-17 2005-05-05 Zentaris Gmbh Novel LHRH-antagonists, production and use thereof as medicament
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US20040138138A1 (en) * 2001-08-02 2004-07-15 Jurgen Engel Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2009145690A1 (en) * 2008-05-29 2009-12-03 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
WO2010004265A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Enzyme-pore constructs
CA2730068A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
EP2391655B1 (en) * 2009-01-30 2017-10-11 Oxford Nanopore Technologies Limited Hybridization linkers
JP5843614B2 (ja) 2009-01-30 2016-01-13 オックスフォード ナノポア テクノロジーズ リミテッド 膜貫通配列決定における核酸構築物のためのアダプター
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
US9751915B2 (en) 2011-02-11 2017-09-05 Oxford Nanopore Technologies Ltd. Mutant pores
EP2737084B1 (en) 2011-07-25 2017-10-18 Oxford Nanopore Technologies Limited Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores
AU2013246702B2 (en) 2012-04-10 2017-06-15 Oxford Nanopore Technologies Limited Mutant lysenin pores
WO2014013259A1 (en) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Ssb method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
CN105209634B (zh) 2013-03-08 2020-05-12 牛津纳米孔技术公司 酶停滞方法
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
WO2015166276A1 (en) 2014-05-02 2015-11-05 Oxford Nanopore Technologies Limited Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
JP7161291B2 (ja) 2014-09-01 2022-10-26 ブイアイビー ブイゼットダブリュ 変異体ポア
EP3204511B1 (en) 2014-10-07 2021-07-28 Oxford Nanopore Technologies Limited Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
CN105837674A (zh) * 2016-03-08 2016-08-10 无限极（中国）有限公司 一种东方铃蟾多肽及其制备方法与应用
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
WO1989009229A1 (en) * 1988-03-31 1989-10-05 Immunobiology Research Institute, Inc. Treatment of hiv viremic patients with thymopentin
EP0438519B1 (en) * 1988-10-14 1998-05-06 The Administrators of The Tulane Educational Fund Therapeutic peptides
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Also Published As

Publication number Publication date
NO320945B1 (no) 2006-02-20
ZA944347B (en) 1995-02-15
CZ285997B6 (cs) 1999-12-15
DE59410052D1 (de) 2002-03-21
WO1995000168A1 (de) 1995-01-05
CN1136915C (zh) 2004-02-04
JPH08511784A (ja) 1996-12-10
NO954996D0 (no) 1995-12-08
ES2172533T3 (es) 2002-10-01
HUT73673A (en) 1996-09-30
PL175580B1 (pl) 1999-01-29
KR960703015A (ko) 1996-06-19
TW370532B (en) 1999-09-21
CN1125400A (zh) 1996-06-26
DK0703786T3 (da) 2002-05-27
FI956014A0 (fi) 1995-12-14
BR9406893A (pt) 1996-09-10
US5985834A (en) 1999-11-16
FI956014A (fi) 1995-12-14
EP0703786B1 (de) 2002-02-13
RU2154492C2 (ru) 2000-08-20
IL110045A (en) 2000-06-01
IL110045A0 (en) 1994-10-07
UA41938C2 (uk) 2001-10-15
EP0703786A1 (de) 1996-04-03
CZ308995A3 (en) 1996-03-13
KR100352541B1 (ko) 2002-12-26
ATE213164T1 (de) 2002-02-15
PT703786E (pt) 2002-07-31
FI113008B (fi) 2004-02-27
PL312219A1 (en) 1996-04-01
HU9503605D0 (en) 1996-02-28
AU688315B2 (en) 1998-03-12
AU6564794A (en) 1995-01-17
DE4320201A1 (de) 1995-01-12
NO954996L (no) 1995-12-08

Similar Documents

Publication Publication Date Title
ZA944347B (en) The use of cetrorelix and other nona- and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
AU684059B2 (en) Application of riluzole in the treatment of Parkinson's disease and Parkinsonian syndromes
MY164077A (en) Compositions and uses of et743 for treating cancer
CA2294921A1 (en) Levobupivacaine and its use
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
EP0744176A3 (en) Methods for inhibiting bone loss
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
IL131478A0 (en) Methods for treatment of scar tissue
AU7460894A (en) Use of 4'-iodo-4'-deoxydoxorubicin for the treatment of amyloidosis
CA2233677A1 (en) A novel combination of a .beta.-receptor blocker and an opioid
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
CA2162468A1 (en) Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases